EOC: Immutep's Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

(marketscreener.com) Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma's phase I study in metastatic breast cancer Data expected throughout 2020, with study completion in Q4 CY2020Registration trial in MBC in China is planned SYDNEY, Australia, March 19, 2020 -- Immutep Limited , is pleased to report that it...https://www.marketscreener.com/IMMUTEP-LIMITED-38892320/news/Immutep-s-Partner-EOC-Pharma-Reports-Completion-of-Recruitment-of-Phase-I-Study-of-Efti-30193382/?utm_medium=RSS&utm_content=20200319